Article Information
History
- June 23, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Shohei Yamamoto, Ph.D.1,*,
- Kouki Matsuda, Ph.D.2,3,4,
- Kenji Maeda, Ph.D.2,5,
- Yusuke Oshiro, M.T.6,
- Natsumi Inamura, M.T.6,
- Tetsuya Mizoue, Ph.D.1,†,
- Maki Konishi1,
- Junko S. Takeuchi, Ph.D.7,
- Kumi Horii, R.N.8,
- Mitsuru Ozeki, M.T.6,
- Haruhito Sugiyama, Ph.D.9,
- Hiroaki Mitsuya, Ph.D.2,
- Wataru Sugiura, Ph.D.10 and
- Norio Ohmagari, Ph.D.11
- 1Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
- 2Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan
- 3AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan
- 4Japan Foundation for AIDS Prevention, Tokyo, Japan
- 5Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan
- 6Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan
- 7Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
- 8Infection Control Office, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan
- 9Department of Respiratory Medicine, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan
- 10Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
- 11Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
- ↵*Corresponding author:
Shohei Yamamoto, Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan; email: syamamoto{at}hosp.ncgm.go.jp - ↵†Alternate corresponding authors:
Tetsuya Mizoue, Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan; email: mizoue{at}hosp.ncgm.go.jp
Posted June 23, 2022.
SARS-CoV-2 breakthrough infection during the Delta-dominant epidemic and neutralizing antibodies against Omicron in comparison with the third dose of BNT162b2: a matched analysis
